Caplyta meets main goal in bipolar mania study
Johnson and Johnson reported that its experimental use of Caplyta successfully met the primary goal in a late stage study for treating bipolar mania. The drug significantly reduced symptoms compared to a placebo, offering potential new treatment benefits.
Xurve View
Insights:
Xurve View
JOHNSON & JOHNSON said on Monday morning its experimental use of Caplyta for bipolar mania met the main goal of a late-stage study. The trial advances the drug toward expanding beyond its currently approved indications. Caplyta is central to the company's neuroscience portfolio following its $14.6B acquisition of Intra-Cellular Therapies.
